Title: | Worldwide perspectives on venom allergy |
---|
Authors: | ID Korošec, Peter, Klinika Golnik (Author) ID Jakob, Thilo (Author) ID Harb, Harfi (Author) ID Heddle, Robert (Author) ID Karabus, Sarah (Author) ID Lima Zollner, Ricardo de (Author) ID Šelb, Julij, Klinika Golnik (Author) ID Yu-Hor Thong, Bernard (Author) ID Zaitoun, Fares (Author) ID Golden, David B. K. (Author) ID Levin, Michael (Author) |
Files: | PDF - Presentation file, download (313,42 KB) MD5: C7FF2C15568B3980F7C9008F4E075B1F
URL - Source URL, visit https://www.worldallergyorganizationjournal.org/article/S1939-4551(19)31221-9/fulltext
|
---|
Language: | English |
---|
Typology: | 1.02 - Review Article |
---|
Organization: | UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
|
---|
Abstract: | Venom immunotherapy is the standard of care for people with severe reactions and has been proven to reduce risk of future anaphylactic events. There is a moral imperative to ensure production, supply and worldwide availability of locally relevant, registered, standardized commercial venom extracts for diagnosis and treatment. Insects causing severe immediate allergic reactions vary by region worldwide. The most common culprits include honeybees (Apis mellifera), social wasps including yellow jackets (Vespula and Dolichovespula), paper wasps (Polistes) and hornets (Vespa), stinging ants (Solenopsis, Myrmecia, Pachycondyla, and Pogonomyrmex), and bumblebees (Bombus). Insects with importance in specific areas of the world include the Australian tick (Ixodes holocyclus), the kissing bug (Triatoma spp), horseflies (Tabanus spp), and mosquitoes (Aedes, Culex, Anopheles). Reliable access to high quality venom immunotherapy to locally relevant allergens is not available throughout the world. Many current commercially available therapeutic vaccines have deficiencies, are not suitable for, or are unavailable in vast areas of the globe. New products are required to replace products that are unstandardized or inadequate, particularly whole-body extract products. New products are required for insects in which no current treatment options exist. Venom immunotherapy should be promoted throughout the world and the provision thereof be supported by health authorities, regulatory authorities and all sectors of the health care service. |
---|
Keywords: | allergy and immunology, venoms, Hymenoptera, bee venoms, wasp venoms, insecta, ants hornet, bumblebee, mosquitoes, venom immunotherapy, immunologic desensitization |
---|
Publication status: | Published |
---|
Publication version: | Version of Record |
---|
Place of publishing: | Velika Britanija |
---|
Publisher: | Elsevier |
---|
Year of publishing: | 2019 |
---|
Number of pages: | str. 1-11 |
---|
Numbering: | Vol. 12, iss. 10 |
---|
PID: | 20.500.12556/DiRROS-12435 |
---|
UDC: | 616-097 |
---|
ISSN on article: | 1939-4551 |
---|
DOI: | 10.1016/j.waojou.2019.100067 |
---|
COBISS.SI-ID: | 2048568945 |
---|
Copyright: | © 2019 The Authors |
---|
Note: | Soavtor iz Slovenije: Julij Selb;
"Korosec and Jakob were joint first authors" --> str. 1;
Nasl. z nasl. zaslona;
Opis vira z dne 8. 11. 2019;
Št. članka: 10067;
|
---|
Publication date in DiRROS: | 23.09.2020 |
---|
Views: | 2268 |
---|
Downloads: | 1262 |
---|
Metadata: | |
---|
:
|
Copy citation |
---|
| | | Share: | |
---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |